Newest Short Interest Filing: What’s Cidara Therapeutics Incorporated (NASDAQ:CDTX) Upside After This Short Interest Increase?

November 29, 2016 - By Richard Conner   ·   0 Comments

Newest Short Interest Filing: What's Cidara Therapeutics Incorporated (NASDAQ:CDTX) Upside After This Short Interest Increase?

The stock of Cidara Therapeutics Incorporated (NASDAQ:CDTX) registered an increase of 19.28% in short interest. CDTX’s total short interest was 379,300 shares in November as published by FINRA. Its up 19.28% from 318,000 shares, reported previously. With 98,900 shares average volume, it will take short sellers 4 days to cover their CDTX’s short positions. The short interest to Cidara Therapeutics Incorporated’s float is 4.66%. The stock decreased 1.84% or $0.2 during the last trading session, hitting $10.65. Cidara Therapeutics Inc (NASDAQ:CDTX) has declined 24.68% since April 26, 2016 and is downtrending. It has underperformed by 29.94% the S&P500.

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The company has a market cap of $174.36 million. The Firm is engaged in the discovery, development and commercialization of anti-infectives. It currently has negative earnings. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

CDTX Company Profile

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., incorporated on December 06, 2012, is a clinical-stage biotechnology company. The Firm is engaged in the discovery, development and commercialization of anti-infectives. The Firm is developing a pipeline of product and development candidates, with a focus on serious fungal infections. The Company’s lead clinical candidates are echinocandins, a class of antifungals. The Company’s product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. In addition, it has developed an immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. It is evaluating Cloudbreak candidates for the treatment of invasive fungal infections, including aspergillosis, an infection caused by the fungal pathogen, Aspergillus.

More recent Cidara Therapeutics Inc (NASDAQ:CDTX) news were published by: Businesswire.com which released: “Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of …” on November 28, 2016. Also Zacks.com published the news titled: “Is Cidara Therapeutics (CDTX) Stock a Solid Choice Right Now?” on November 25, 2016. Globenewswire.com‘s news article titled: “Cidara Therapeutics Expands Management Team” with publication date: July 05, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Richard Conner


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>